BONESUPPORT Q2: Initial take – beat on sales, miss on EBIT - Redeye

Redeye sees that the sales beat and updated sales growth target for 2024e will excite the market. Still, questions and uncertainties regarding its increasing costs (potentially delaying an accelerating EBIT margin) and large changes in working capital may pose a dampened share price reaction. However, things continue to align well for BONESUPPORT, and we are prone to making slight upward changes in our base case.

Länk till analysen i sin helhet: https://www.redeye.se/research/1021028/bonesupport-q2-initial-take-beat-on-sales-miss-on-ebit?utm_source=finwire&utm_medium=RSS